Compare Novavax Inc (NVAX) vs Nextpower Inc. Common Stock (NXT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Nextpower Inc. Common Stock — how do they compare? Novavax Inc trades at $12.46 (market cap $2.11B), while Nextpower Inc. Common Stock trades at $81.37 (market cap $13.47B). The key difference: Nextpower Inc. Common Stock is far larger — about 6.4× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Nextpower Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Nextpower Inc. Common Stock for 0 Days on average.
| NVAX | NXT | |
|---|---|---|
Market Cap | $2.11B | $13.47B |
Volume | 8,376,831 | 2,009,302 |
Sector | Health | Energy |
52-Week High | $12.82 | $156.40 |
52-Week Low | $6.22 | $77.93 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $1.69B | $12.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.64, down slightly by 0.16% on the day. The stock shows a bullish technical signal with strong moving average and oscillator support. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of -$0.32 surpassing the -$0.38 estimate. The company is transitioning its business model toward a partnership-driven approach centered on its Matrix-M adjuvant technology, with recent regulatory approvals for its updated COVID-19 vaccine in major markets.
The outlook is mixed with strong analyst buy ratings (73.9%) and recent business developments providing catalysts, but significant financial risks remain including negative cash flows, high debt levels, and inconsistent profitability. Investment opportunity exists in the partnership strategy execution, while risks include execution challenges and competitive pressures in the vaccine market.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →
